FGF-2 Polyclonal Antibody
¥680.00
PKR (phospho Thr258) Polyclonal Antibody
活动价：
¥680.00
市场价：¥880.00
一键复制产品信息
产品规格：
- 50μL
- 100μL
货号：
FAB2611576
- 产品信息
商品描述
靶点-Target
PKR
反应性
Human,Rat,Mouse,
应用
WB,IHC,IF,ELISA
宿主物种-Host Species
Rabbit
同种型-Isotype
IgG
修饰-Modification
Phospho
MW(Observed)
62kD
推荐稀释比
WB 1:500-1:2000;IHC 1:100-1:300;ELISA 1:20000;IF 1:50-200
组成
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
纯化工艺
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
储存
-15°C to -25°C/1 year(Do not lower than -25°C)
浓度
1 mg/ml
克隆性
Polyclonal
免疫原
The antiserum was produced against synthesized peptide derived from human PKR around the phosphorylation site of Thr258. AA range:226-275
特异性
Phospho-PKR (T258) Polyclonal Antibody detects endogenous levels of PKR protein only when phosphorylated at T258.
基因名称
EIF2AK2
蛋白名称
Interferon-induced double-stranded RNA-activated protein kinase
别名
EIF2AK2;PKR;PRKR;Interferon-induced;double-stranded RNA-activated protein kinase;Eukaryotic translation initiation factor 2-alpha kinase 2;eIF-2A protein kinase 2;Interferon-inducible RNA-dependent protein kinase;P1/eIF-2A protein k
Organism-1
Human
基因ID-1
5610
SwissProt-1
P19525
Organism-2
Mouse
SwissProt-2
Q03963
背景
The protein encoded by this gene is a serine/threonine protein kinase that is activated by autophosphorylation after binding to dsRNA. The activated form of the encoded protein can phosphorylate translation initiation factor EIF2S1, which in turn inhibits protein synthesis. This protein is also activated by manganese ions and heparin. Three transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Oct 2011],
细胞定位
Cytoplasm . Nucleus . Cytoplasm, perinuclear region . Nuclear localization is elevated in acute leukemia, myelodysplastic syndrome (MDS), melanoma, breast, colon, prostate and lung cancer patient samples or cell lines as well as neurocytes from advanced Creutzfeldt-Jakob disease patients. .
